Adaptimmune announces partnership with GSK for cell-based cancer
5 June 2014
Adaptimmune Limited has announced a multi-million dollar
strategic collaboration and licensing agreement with GlaxoSmithKline
(GSK) for the development and commercialisation of its lead clinical
It is believed to be one of the largest deals in the UK life
sciences sector in 2014. According to the agreed development plan,
the deal could yield payments in excess of $350 million to
Adaptimmune over the next seven years, together with significant
additional development and commercialisation payments becoming due
in subsequent years if GSK exercises all its options and milestones
continue to be met. In addition, Adaptimmune would also receive
tiered royalties ranging from single to double digits on net sales.
Adaptimmune is focused on using the body’s own machinery – the T
cell – to target and destroy cancerous or infected cells by using
engineered, increased affinity T cell receptor (TCRs) as a means of
strengthening a patient’s natural T cell responses. The company has
ongoing clinical programmes in multiple cancer indications with its
NY-ESO-1/LAGE-1 cancer testis antigen. European trials are set to
commence shortly and the company has also announced that it is
taking a second T cell-based therapy into the clinic in triple
negative breach cancer in 2015.
Under the terms of the agreement with GSK, Adaptimmune will
co-develop its NY-ESO-1 clinical programme and associated
manufacturing optimisation work together with GSK. GSK will have an
option on the NY-ESO-1 programme through clinical proof of concept,
anticipated during 2016, and, on exercise, will assume full
responsibility for the programme. The companies will also co-develop
other TCR target programmes and collaborate on further optimization
of engineered TCR products.
James Noble, Chief Executive Officer of Adaptimmune, commented:
“We are delighted to collaborate with GSK, a leading pharmaceutical
company which has made a strategic commitment to immuno-oncology.
Its substantial development and manufacturing expertise in key areas
will be invaluable as we work together to accelerate the development
of our programmes and bring potentially breakthrough cancer
therapies to patients.